Evidence map›Paper›PMID 32647353›Full record

Trial reportProstate cancer and prostatic diseases2021

The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells.

Nicholas G Nickols, Ekambaram Ganapathy, Christine Nguyen, Nathanael Kane, Lin Lin, Silvia Diaz-Perez, Ramin Nazarian, Colleen Mathis, Care Felix, Vince Basehart and 14 more

Open access · greenAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  5. Article
  6. Review
  7. Review
  8. PSA bounce, prognosis, and clues to the radiation response.Prostate cancer and prostatic diseases · 2021
    Article
  9. Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancer.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2021
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 1 country.

Nicholas G NickolsRadiation Oncology at UCLA, Los Angeles, CA, USA.
Ekambaram GanapathyRadiation Oncology at UCLA, Los Angeles, CA, USA.
Christine NguyenRadiation Oncology at UCLA, Los Angeles, CA, USA.
Nathanael KaneRadiation Oncology at UCLA, Los Angeles, CA, USA.
Lin LinUrology at UCLA, Los Angeles, CA, USA.
Silvia Diaz-PerezRadiation Oncology at UCLA, Los Angeles, CA, USA.
Ramin NazarianUrology at UCLA, Los Angeles, CA, USA.
Colleen MathisUrology at UCLA, Los Angeles, CA, USA.
Care FelixRadiation Oncology at UCLA, Los Angeles, CA, USA.
Vince BasehartRadiation Oncology at UCLA, Los Angeles, CA, USA.
Nazy ZomorodianUrology at UCLA, Los Angeles, CA, USA.
Jae KwakUrology at UCLA, Los Angeles, CA, USA.
Amar U KishanRadiation Oncology at UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-7437-6591
Christopher R KingRadiation Oncology at UCLA, Los Angeles, CA, USA.
Patrick A KupelianRadiation Oncology at UCLA, Los Angeles, CA, USA.
Matthew B RettigUrology at UCLA, Los Angeles, CA, USA.
Michael L SteinbergRadiation Oncology at UCLA, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-4292-5824
Minsong CaoRadiation Oncology at UCLA, Los Angeles, CA, USA.
Beatrice S KnudsenPathology and Laboratory Medicine and Biomedical Sciences at Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Fang-I ChuRadiation Oncology at UCLA, Los Angeles, CA, USA.
Tahmineh RomeroDivision of General Internal Medicine and Health Services Research at UCLA, Los Angeles, CA, USA.
David ElashoffUCLA Jonsson Compressive Cancer Center, Los Angeles, CA, USA.
Robert E ReiterUrology at UCLA, Los Angeles, CA, USA.
Dörthe SchaueRadiation Oncology at UCLA, Los Angeles, CA, USA. dschaue@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-5674-678X
UCLA Health · USRadiation Oncology Associates · USCedars-Sinai Medical Center · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Beth A. Glenn · 1985 to 2026
$134.5M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
Radiotherapy-induced tumor immunityR01CA191234 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCHAUE, DORTHE · 2015 to 2019
$1.8M
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate CancerI01CX001575 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI NICKOLS, NICHOLAS GEORGE · 2018 to 2023
–
CSRD VA I01 CX001575NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA191234
6 · The paper itself

Abstract

backgroundHundreds of ongoing clinical trials combine radiation therapy, mostly delivered as stereotactic body radiotherapy (SBRT), with immune checkpoint blockade. However, our understanding of the effect of radiotherapy on the intratumoral immune balance is inadequate, hindering the optimal design of trials that combine radiation therapy with immunotherapy. Our objective was to characterize the intratumoral immune balance of the malignant prostate after SBRT in patients.

methodsSixteen patients with high-risk, non-metastatic prostate cancer at comparable Gleason Grade disease underwent radical prostatectomy with (n = 9) or without (n = 7) neoadjuvant SBRT delivered in three fractions of 8 Gy over 5 days completed 2 weeks before surgery. Freshly resected prostate specimens were processed to obtain single-cell suspensions, and immune-phenotyped for major lymphoid and myeloid cell subsets by staining with two separate 14-antibody panels and multicolor flow cytometry analysis.

resultsMalignant prostates 2 weeks after SBRT had an immune infiltrate dominated by myeloid cells, whereas malignant prostates without preoperative treatment were more lymphoid-biased (myeloid CD45

conclusionSBRT drives a significant lymphoid to myeloid shift in the prostate-tumor immune infiltrate. This may be of interest when combining SBRT with immunotherapies, particularly in prostate cancer.

Indexed as

HumansImmunotherapyInjections, IntralymphaticMaleMiddle AgedMyeloid CellsNeoadjuvant TherapyNeoplasm GradingProstateProstatectomyProstatic NeoplasmsQuality of LifeRadiosurgery

Identifiers

PMID32647353
PMCPMC7794088
OpenAlexW3041271951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.